Professional Media briefs: September 2012

Professional Media briefs: September 2012
Professional Media briefs: September 2012

Elsevier increased its open-access lineup with the July launch of Applied Translational Genomics. Editor-in-Chief Dhavendra Kumar (pictured) and the 13-member editorial board are overseeing the journal, which covers topics such as comparative genomics, applied bio-systems, and ethical, legal and social issues in translational genomics. The Dutch publisher also announced changes in its editorial staff for its publication Neurobiology of Learning and Memory. Ted Abel has been named Editor-In-Chief, replacing John Guzowski.

Springer is launching a new series of books with the Breast Cancer Research Foundation. The collaboration will officially begin in 2013, and will result in four books over the next four years. The publications will be part of Springer's Advances in Experimental Medicine and Biology series.

Yale New-Haven Hospital Chief of Cardiothoracic Surgery John Elefteriades has been named co-Editor-in-Chief of The International Journal of Angiology. His counterpart is co-chief John Chang. Publisher Thieme also announced that it has added two additional chairs around the publication's table, including that of Consulting Editor Kailash Prasad and Senior Editor Otmar Pachinger.
You must be a registered member of MMM to post a comment.

Email Newsletters

What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.

A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.